What changed in this filing

/stocks — the workspaceLOADING

Item 1. Financial Statements

2020-11-02 compared with 2020-08-06 · 279 added, 215 removed, 1491 unchanged (25% of the section changed)

Financial Statements.

30, 2020 (UNAUDITED) AND DECEMBER 31, 2019

BALANCE SHEETS

SEPTEMBER 30, 2020 (UNAUDITED) AND DECEMBER 31, 2019

SEPTEMBER 30,

Current Assets:

AND STOCKHOLDERS' DEFICIT

payable and accrued expenses

party accounts payable

interest payable

liabilities payable

notes payable, related party, net

notes payable, net

notes payable, net of discount

party promissory note

Prepaid expenses

Total Current Assets

LIABILITIES AND STOCKHOLDERS’

Current Liabilities:

and contingencies

STOCKHOLDERS'

stock, par value, $0.001, 20,000,000 shares authorized, Series A Convertible Preferred, 5,000,000 shares authorized, 2,552,642

Accounts payable and accrued expenses

Related party accounts payable

Accrued interest payable

Payroll liabilities payable

Convertible notes payable, related party, net

Convertible notes payable, net

Promissory notes payable, net of discount

Related party promissory note

Total Current Liabilities

Total Liabilities

Commitments and contingencies

STOCKHOLDERS’

Preferred stock, par value, $0.001, 20,000,000 shares authorized, Series A

Convertible Preferred, 5,000,000 shares authorized, 2,552,642 shares issued and outstanding, respectively

Additional paid in capital - Series A Convertible preferred stock

Series B Convertible Preferred, 5,000,000 shares authorized, 1,013,245 and

1,113,245 shares issued and outstanding, respectively

paid in capital - Series A Convertible preferred stock

B Convertible Preferred, 5,000,000 shares authorized, 1,013,245 and 1,113,245 shares issued and outstanding, respectively

paid in capital - Series B Convertible preferred stock

C Convertible Preferred, 5,000,000 shares authorized, 385,302 and 821,292 shares issued and outstanding, respectively

paid in capital - Series C Convertible preferred stock

stock, par value, $0.001, 950,000,000 shares authorized, 232,848,376 and 184,845,821 issued and outstanding, respectively

paid in capital - common stock

Additional paid in capital - Series B Convertible preferred stock

Series C Convertible Preferred, 5,000,000 shares authorized, 385,302 and

821,292 shares issued and outstanding, respectively

Additional paid in capital - Series C Convertible preferred stock

Common stock, par value, $0.001, 950,000,000 shares authorized, 234,700,228

and 184,845,821 issued and outstanding, respectively

Additional paid in capital - common stock

Shares to be issued

Accumulated deficit

(74,256,018 )

(73,601,109 )

Stockholders' Deficit

LIABILITIES AND STOCKHOLDERS' DEFICIT

The accompanying notes are an integral part of these financial statements.

STATEMENTS OF OPERATIONS (UNAUDITED)

THE SIX AND THREE MONTHS ENDED JUNE 30, 2020 AND 2019

revenues, net

based compensation

and development

and administrative expenses

Total Stockholders’

TOTAL LIABILITIES AND STOCKHOLDERS’

accompanying notes are an integral part of these financial statements.

CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED)

FOR THE NINE AND THREE MONTHS ENDED SEPTEMBER 30, 2020 AND 2019

NINE MONTHS ENDED

THREE MONTHS ENDED

SEPTEMBER 30,

Consulting revenues, net

OPERATING EXPENSES

NON-OPERATING

INCOME (EXPENSE)

Non-Operating Income (Expenses)

LOSS BEFORE PROVISION FOR INCOME TAXES

for income taxes

loss per share - basic and diluted

average common shares outstanding - basic

The accompanying notes are an integral part of these financial statements.

OF CHANGES IN STOCKHOLDERS’

THE SIX MONTHS ENDED JUNE 30, 2020 (UNAUDITED) AND DECEMBER 31, 2019

Professional fees

Stock based compensation

Payroll expenses

Research and development

General and administrative expenses

Total Operating Expenses

OPERATING LOSS

NON-OPERATING INCOME (EXPENSE)

Interest expense

Total Non-Operating Income (Expenses)

NET LOSS BEFORE PROVISION FOR INCOME TAXES

Provision for income taxes

$ (1,106,059 )

Net loss per share - basic and diluted

Weighted average common shares outstanding - basic

accompanying notes are an integral part of these financial statements.

OF CHANGES IN STOCKHOLDERS' DEFICIT

THE NINE MONTHS ENDED SEPTEMBER 30, 2020 (UNAUDITED) AND DECEMBER 31, 2019

- December 31, 2018

38 unchanged sentences

(73,961,340 )

conversions/settlements

purchased for cash

3 unchanged sentences

$ (74,120,427 )

conversions/settlements

loss for the period

- September 30, 2020

$ (74,256,018 )

accompanying notes are an integral part of these financial statements.

OF CASH FLOWS

THE SIX MONTHS ENDED JUNE 30, 2020 AND 2019 (UNAUDITED)

THE NINE MONTHS ENDED SEPTEMBER 30, 2020 AND 2019 (UNAUDITED)

CASH FLOW FROM OPERTING ACTIVIITES

$ (1,106,059 )

Adjustments to reconcile net loss to net cash used in operating activities

1 unchanged sentence

Amortization of BCF discount

Common stock issued for services

Stock options and warrants for services

Forgiveness of debt

Warrants issued for interest expense

16 unchanged sentences

Proceeds from promnissory notes

Proceeds from related party advances, net of repayments

Payment of notes payable

Net cash provided by financing activities

9 unchanged sentences

Conversion of notes payable and accrued interest into common stock

Recognition of BCF discount at inception of notes payable

Common stock issued in settlement of accounts payable

Stock options issued in settlement of accounts payable

Reclassification of notes payable and accrued interest into common stock

accompanying notes are an integral part of these financial statements.

87 unchanged sentences

See also Business –

Regulatory History in Part I of this Annual Report

Regulatory History in Part I of the Annual Report

on Form 10-K (“

Annual Report ”) for a discussion regarding the Company’s application for FDA approval

of RadioGel™.

Annual Report ”) filed April 28, 2020 for a discussion regarding the Company’s application

for FDA approval of RadioGel™.

Company’s IsoPet Solutions division was established in May 2016 to focus on the veterinary oncology market, namely engagement

99 unchanged sentences

consisted of finished goods.

The Company has no inventory for the six-months ended June 30, 2020 and for the year ended December

The Company has no inventory for the nine-months ended September 30, 2020 and for the year ended

December 31, 2019.

Value of Financial Instruments

1 unchanged sentence

where it is practicable to estimate that value.

As of June 30, 2020 and December 31, 2019, the balances reported for cash, prepaid

expenses, accounts receivable, accounts payable, and accrued expenses, approximate the fair value because of their short maturities.

As of September 30, 2020 and December 31, 2019, the balances reported for cash,

prepaid expenses, accounts receivable, accounts payable, and accrued expenses, approximate the fair value because of their short

value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction

105 unchanged sentences

operating results and projected and expected undiscounted future cash flows.

have been no such capitalized costs in the three-months ended March 31, 2020 and 2019, respectively.

have been no such capitalized costs in the nine-months ended June 30, 2020 and 2019, respectively.

However, a patent was filed

29 unchanged sentences

performance obligation.

revenue generated during the year ended December 31, 2019 related to sales of product.

revenue generated during the nine months ended September 30, 2020 and year ended December 31, 2019 related to sales of product.

Company accounts for its loss per common share by replacing primary and fully diluted earnings per share with basic and diluted

7 unchanged sentences

For the given periods of loss,

of the periods ended in the six months ended June 30, 2020 and 2019, the basic earnings per share equals the diluted earnings

following represent common stock equivalents that could be dilutive in the future as of June 30, 2020 and December 31, 2019, which

include the following:

June 30, 2020

of the periods ended in the nine months ended September 30, 2020 and 2019, the basic earnings per share equals the diluted earnings

following represent common stock equivalents that could be dilutive in the future as of September 30, 2020 and December 31, 2019,

which include the following:

September 30, 2020

December 31, 2019

10 unchanged sentences

and development is classified as research and development expense in the year computed.

Company incurred $17,425 and $43,702 research and development costs for the six months ended June 30, 2020, and 2019, respectively,

all of which were recorded in the Company’s operating expenses noted on the statements of operations for the three months

Company incurred $31,809 and $62,194 research and development costs for the nine months ended September 30, 2020, and 2019, respectively,

all of which were recorded in the Company’s operating expenses noted on the statements of operations for the nine months

and Marketing Costs

and marketing costs are expensed as incurred except for the cost of tradeshows which are deferred until the tradeshow occurs.

There were no tradeshow expenses incurred and not expensed for the six months ended June 30, 2020, and 2019, respectively.

the six months ended June 30, 2020 and 2019, the Company incurred $5,132 and $0, respectively, in advertising and marketing costs.

During the nine months ended September 30, 2020 and 2019, the Company incurred $6,182 and $0, respectively, in advertising and

marketing costs.

and Handling Costs

12 unchanged sentences

The Company has entered into various agreements that require them to pay certain fees to consultants and/or employees

that have been fully accrued for as of June 30, 2020 and December 31, 2019.

that have been fully accrued for as of September 30, 2020 and December 31, 2019.

address accounting for uncertainty in tax positions, the Company clarifies the accounting for income taxes by prescribing a minimum

4 unchanged sentences

federal jurisdiction.

The Company did not have any tax expense for the six months

ended June 30, 2020 and 2019.

The Company did not have any deferred tax liability or asset on its balance sheet on June 30, 2020

The Company did not have any tax expense for the nine months

ended September 30, 2020 and 2019.

The Company did not have any deferred tax liability or asset on its balance sheet on September

30, 2020 and December 31, 2019.

1 unchanged sentence

respectively, in the Company’s financial statements.

For the six months ended June 30, 2020 and 2019, the Company did not

recognize any interest or penalty expense related to income taxes.

The Company believes that it is not reasonably possible for

the amounts of unrecognized tax benefits to significantly increase or decrease within the next twelve months.

For the nine months ended September 30, 2020 and 2019, the Company

did not recognize any interest or penalty expense related to income taxes.

The Company believes that it is not reasonably possible

for the amounts of unrecognized tax benefits to significantly increase or decrease within the next twelve months.

Company recognizes compensation costs to employees under FASB ASC Topic 718, Compensation –

41 unchanged sentences

Accounting Pronouncements

standards that have been issued or proposed by FASB that do not require adoption until a future date are not expected to have

a material impact on the consolidated financial statements upon adoption.

The Company does not discuss recent pronouncements that

are not anticipated to have an impact on or are unrelated to its financial condition, results of operations, cash flows or disclosures.

August, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No.

2020-06, Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging-Contracts in Entity’s Own

Equity (Subtopic 815-40), Accounting for Convertible Instruments and Contract’s in an Entity’s Own Equity.

simplifies accounting for convertible instruments by removing major separation models required under current GAAP.

Consequently,

more convertible debt instruments will be reported as a single liability instrument with no separate accounting for embedded conversion

The ASU removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope

exception, which will permit more equity contracts to qualify for it.

The ASU simplifies the diluted net income per share calculation

in certain areas.

The ASU is effective for annual and interim periods beginning after December 31, 2021, and early adoption is

permitted for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years.

The Company is currently

evaluating the impact that this new guidance will have on its financial statements.

Company does not discuss recent pronouncements that are not anticipated to have an impact on or are unrelated to its financial

condition, results of operations, cash flows or disclosures.

GOING CONCERN

10 unchanged sentences

on June 3, 2020 and have issued the first tranche of shares under the Regulation A+ on June 10, 2020.

intent is to raise up to $4,050,000 over the next 12-18 months, which may be completed in separate closings.

The intent is to raise up

to $4,050,000 over the next 12-18 months, which may be completed in separate closings.

Company intends to use the proceeds generated from the sale of shares under Regulation A+ as follows:

15 unchanged sentences

exchanged their outstanding convertible notes payable of $525,000, $27,536 in accrued interest and $98,508 in an exchange premium

stipulated in the note agreements into shares of common stock through June 30, 2020.

stipulated in the note agreements into shares of common stock through September 30, 2020.

the next 12 to 24 months, the Company believes it will cost approximately $5.0 million to $10.0 million to:

36 unchanged sentences

The Company is hopeful that by the

end of the third quarter of 2020, they will be allowed to continue their marketing to the animal therapy market and attempt to

increase the exposure to their product and generate revenue accordingly.

end of 2020 into the first quarter of 2021, they will be allowed to continue their marketing to the animal therapy market and

attempt to increase the exposure to their product and generate revenue accordingly.

financial statements do not include any adjustments relating to the recoverability and classification of liabilities that might

10 unchanged sentences

this uncertainty.

of June 30, 2020, the Company has $248,855 cash on hand.

of September 30, 2020, the Company has $14,934 cash on hand.

There are currently commitments to vendors for products and services

26 unchanged sentences

this uncertainty.

assets consist of the following at June 30, 2020 (unaudited) and December 31, 2019:

June 30, 2020

December 31, 2019

Production equipment

Less accumulated depreciation

is no depreciation expense for the above fixed assets for the six months ended June 30, 2020 and 2019, respectively.

In June 2019,

the Company sold the one piece of equipment still held for $0.

The basis of this piece of equipment was also $0, resulting in

no gain or loss on the sale.

assets consist of the following at September 30, 2020 (unaudited) and December 31, 2019:

accumulated depreciation

is no depreciation expense for the above fixed assets for the nine months ended September 30, 2020 and 2019, respectively.

June 2019, the Company sold the one piece of equipment still held for $0.

The basis of this piece of equipment was also $0, resulting

in no gain or loss on the sale.

RELATED PARTY TRANSACTIONS

Party Convertible Notes Payable

of June 30, 2020 and December 31, 2019, the Company had the following related party convertible notes outstanding:

June 30, 2020

of September 30, 2020 and December 31, 2019, the Company had the following related party convertible notes outstanding:

September 30, 2020

December 31, 2019

33 unchanged sentences

the interest rate charged was changed to 12.5% through conversion of this note in April 2020.

expense for the six months ended June 30, 2020 and 2019 on the related party convertible notes payable amounted to $298 and $0,

respectively.

expense for the nine months ended September 30, 2020 and 2019 on the related party convertible notes payable amounted to $298

and $0, respectively.

Party Notes Payable

of June 30, 2020 and December 31, 2019, the Company had the following related party notes outstanding:

June 30, 2020

of September 30, 2020 and December 31, 2019, the Company had the following related party notes outstanding:

September 30, 2020

December 31, 2019

21 unchanged sentences

The note is for a one-year period maturing November 25, 2020 and bears interest at an annual rate of

Interest expense for these notes for the six months ended June 30, 2020 and 2019 was $9,429 and $3,658, respectively and accrued

interest at June 30, 2020 is $20,736.

Company borrowed $87,000 in the six months ended June 30, 2020 from its CEO and repaid these amounts in full.

Interest expense for these notes for the nine months ended September 30, 2020 and 2019 was $14,194 and $7,155, respectively

and accrued interest at September 30, 2020 is $25,502.

Company borrowed $87,000 in the nine months ended September 30, 2020 from its CEO and repaid these amounts in full.

Party Payables

Company periodically receives advances for operating funds from related parties or has related parties make payments on the Company’s

As a result of these activities the Company had related party payables of $32,110 and $32,110 as of June 30, 2020 and

December 31, 2019, respectively.

As a result of these activities the Company had related party payables of $32,110 and $32,110 as of September 30, 2020

and December 31, 2019, respectively.

and Common Shares Issued to Officers and Directors

7 unchanged sentences

CONVERTIBLE NOTES PAYABLE

of June 30, 2020 and December 31, 2019, the Company had the following convertible notes outstanding:

June 30, 2020

of September 30, 2020 and December 31, 2019, the Company had the following convertible notes outstanding:

September 30, 2020

December 31, 2019

and August 2012 $1,060,000 Notes convertible into common stock at $4.60 per share, 12% interest, due December 2013 and January

through October 2015 $605,000 Notes convertible into preferred stock at $1 per share, 8-10% interest, due September 30, 2015

through December 2015 $613,000 Notes convertible into preferred stock at $1 per share, 8% interest, due June 30, 2016, net

of debt discount of $0 and $560,913, respectively

through March 2016 $345,000 Notes convertible into preferred stock at $1 per share, 8% interest, due June 30, 2016

2019 $60,000 Note convertible into common shares at $0.04 per share, 8% interest, due October 30, 2019

2019 $50,000 Note convertible into common shares at $0.04 per share, 8% interest, due January 15, 2020

2019 $38,000 Note convertible into common shares at $0.04 per share, 8% interest, due January 15, 2020

2019 $25,000 Note convertible into common shares at $0.04 per share, 8% interest, due January 15, 2020

2019 $50,000 Note convertible into common shares at $0.04 per share, 8% interest, due January 15, 2020

2019 $37,000 Note convertible into common shares at $0.04 per share, 8% interest, due January 15, 2020

2019 $50,000 Note convertible into common shares at $0.04 per share, 8% interest, due March 31, 2020

2020 $100,000 Note convertible into common shares at $0,04 per share, 8% interest, due March 31, 2020

on notes in default

Convertible Notes Payable, Net

Accrued Interest

July and August 2012 $1,060,000 Notes convertible into common stock at $4.60 per share, 12% interest, due December 2013 and January 2014

May through October 2015 $605,000 Notes convertible into preferred stock at $1 per share, 8-10% interest, due September 30, 2015

October through December 2015 $613,000 Notes convertible into preferred stock at $1 per share, 8% interest, due June 30, 2016, net of debt discount of $0 and $560,913, respectively

January through March 2016 $345,000 Notes convertible into preferred stock at $1 per share, 8% interest, due June 30, 2016

May 2019 $60,000 Note convertible into common shares at $0.04 per share, 8% interest, due October 30, 2019

July 2019 $50,000 Note convertible into common shares at $0.04 per share, 8% interest, due January 15, 2020

September 2019 $50,000 Note convertible into common shares at $0.04 per share, 8% interest, due January 15, 2020

September 2019 $38,000 Note convertible into common shares at $0.04 per share, 8% interest, due January 15, 2020

September 2019 $25,000 Note convertible into common shares at $0.04 per share, 8% interest, due January 15, 2020

September 2019 $50,000 Note convertible into common shares at $0.04 per share, 8% interest, due January 15, 2020

September 2019 $37,000 Note convertible into common shares at $0.04 per share, 8% interest, due January 15, 2020

December 2019 $50,000 Note convertible into common shares at $0.04 per share, 8% interest, due March 31, 2020

January 2020 $100,000 Note convertible into common shares at $0,04 per share, 8% interest, due March 31, 2020

Penalties on notes in default

Total Convertible Notes Payable, Net

Debt Discount

expense for the six months ended June 30, 2020 and 2019 on the convertible notes payable amounted to $18,425 and $3,064, respectively.

expense for the nine months ended September 30, 2020 and 2019 on the convertible notes payable amounted to $19,783 and $7,509,

respectively.

May 2017 notes totaling $3,136,506, $2,419,240 after debt discounts, had a December 2017 due date which was extended to May 2018.

29 unchanged sentences

over the life of the notes.

For the six months ended June 30, 2020 and 2019, the Company recognized $6,187 and $0, in amortization

For the nine months ended September 30, 2020 and 2019, the Company recognized $6,187 and $0, in amortization

of the BCF discount.

1 unchanged sentence

As a result of the default, the interest rate charged

was changed to 12.5% up through the conversion of these note effective March 31, 2020.

was changed to 12.5% up through the conversion of these notes.

Company entered into $50,000 in a convertible promissory note on December 31, 2019, that matures March 31, 2020.

22 unchanged sentences

PROMISSORY NOTES PAYABLE

of June 30, 2020 and December 31, 2019, the Company had the following promissory notes outstanding:

June 30, 2020

of September 30, 2020 and December 31, 2019, the Company had the following promissory notes outstanding:

September 30, 2020

December 31, 2019

15 unchanged sentences

The interest expense on these notes

for the six months ended June 30, 2020 and 2019 amounted to $7,460 and $2,842, and $5,370 is accrued for as of June 30, 2020.

for the nine months ended September 30, 2020 and 2019 amounted to $8,032 and $5,640, and $0 is accrued for as of September 30,

Company repaid $50,00 of these notes plus $13,442 in accrued interest, and settled the remaining $50,000 into 1,851,852 shares

of common stock effective July 14, 2020.

STOCKHOLDERS’

Company has 950,000,000 shares of common stock authorized, with a par value of $0.001, and as of June 30, 2020 and December 31,

Company has 950,000,000 shares of common stock authorized, with a par value of $0.001, and as of September 30, 2020 and December

31, 2019, the Company has 234,700,228 and 184,845,821 shares issued and outstanding, respectively.

2 unchanged sentences

The reverse stock split went effective by FINRA on June 28, 2019.

of June 30, 2020 and December 31, 2019, the Company has 20,000,000 shares of Preferred stock authorized with a par value of $0.001.

The Company’s Board of Directors is authorized to provide for the issuance of shares of preferred stock in one or more series,

fix or alter the designations, preferences, rights, qualifications, limitations or restrictions of the shares of each series,

including the dividend rights, dividend rates, conversion rights, voting rights, term of redemption including sinking fund provisions,

redemption price or prices, liquidation preferences and the number of shares constituting any series or designations of such series

without further vote or action by the shareholders.

The issuance of preferred stock may have the effect of delaying, deferring

or preventing a change in control of management without further action by the shareholders and may adversely affect the voting

and other rights of the holders of common stock.

The issuance of preferred stock with voting and conversion rights may adversely

affect the voting power of the holders of common stock, including the loss of voting control to others.

of September 30, 2020 and December 31, 2019, the Company has 20,000,000 shares of Preferred stock authorized with a par value

The Company’s Board of Directors is authorized to provide for the issuance of shares of preferred stock in one

or more series, fix or alter the designations, preferences, rights, qualifications, limitations or restrictions of the shares

of each series, including the dividend rights, dividend rates, conversion rights, voting rights, term of redemption including

sinking fund provisions, redemption price or prices, liquidation preferences and the number of shares constituting any series

or designations of such series without further vote or action by the shareholders.

The issuance of preferred stock may have the

effect of delaying, deferring or preventing a change in control of management without further action by the shareholders and may

adversely affect the voting and other rights of the holders of common stock.

The issuance of preferred stock with voting and conversion

rights may adversely affect the voting power of the holders of common stock, including the loss of voting control to others.

October 8, 2018 the Company created out of the shares of Preferred Stock, par value $0.001 per share, of the Company, as authorized

185 unchanged sentences

the qualification of the Regulation A+.

the three months ended September 30, 2020, the Company issued 1,851,852 shares of common stock to settle $50,000 in promissory

and Preferred Stock Issuances - 2019

19 unchanged sentences

Options expired

Balance at June 30, 2020

Balance at September 30, 2020

$ 0.024-120.00

Exercisable at June 30, 2020

Exercisable at September 30, 2020

$ 0.024-120.00

30 unchanged sentences

These options were valued at $14,812.

the six months ended June 30, 2020 and 2019, the Company recognized $2,176 and $2,176, respectively, worth of stock based compensation

related to the vesting of it stock options.

the nine months ended September 30, 2020 and 2019, the Company recognized $2,176 and $460,125, respectively, worth of stock based

compensation related to the vesting of it stock options.

Stock Warrants

following schedule summarizes the changes in the Company’s stock warrants:

Average Remaining

Average Exercise

at December 31, 2019

expired/cancelled

at June 30, 2020

Warrants Outstanding

Weighted Average

Remaining Contractual

Aggregate Intrinsic

Balance at December 31, 2019

Warrants granted

Warrants exercised

Warrants expired/cancelled

Balance at September 30, 2020

Exercisable at September 30, 2020

the year ended December 31, 2019, the Company granted 1,250,000 warrants in the issuance of common and preferred shares issued

28 unchanged sentences

RSU’s forfeited

Balance at June 30, 2020

the six months ended June 30.

2020 and 2019, the Company recognized $0 and $0 worth of expense related to the vesting of its RSU’s.

As of June 30, 2020, the Company had $155,400 worth of expense yet to be recognized for RSU’s not yet vested.

Balance at September 30, 2020

the nine months ended September 30.

2020 and 2019, the Company recognized $0 and $0 worth of expense related to the vesting of

its RSU’s.

As of September 30, 2020, the Company had $155,400 worth of expense yet to be recognized for RSU’s not

LEGAL MATTERS

18 unchanged sentences

into on July 21, 2017.

The Company has paid this liability in full as of September 11, 2020.

June 4, 2019, the Company entered into an Executive Employment Agreement (“Employment Agreement”) with Dr.

9 unchanged sentences

will record the deferred compensation at that time.

SUBSEQUENT EVENTS

has evaluated subsequent events, in accordance with FASB ASC Topic 855, “Subsequent Events”, through the date which

the financial statements were available to be issued and there are no material subsequent events to report.

Management’s Discussion and Analysis of Financial Condition and Results of Operations.

228 unchanged sentences

Two other cases were also very

advanced with multiple tumor and they recurred since they had already spread before therapy.

advanced with multiple tumors and they recurred since they had already spread before therapy.

Company’s efforts are now to obtain more early stage cancer patients.

69 unchanged sentences

of Operations

of the Six Months Ended June 30, 2020 and 2019

following table sets forth information from our statements of operations for the six months ended June 30, 2020 and 2019:

Six Months Ended

June 30, 2020

Six Months Ended

June 30, 2019

of the Nine Months Ended September 30, 2020 and 2019

following table sets forth information from our statements of operations for the nine months ended September 30, 2020 and 2019:

Nine Months Ended

September 30, 2020

Nine Months Ended

September 30, 2019

Operating expenses

2 unchanged sentences

Interest expense

was $0 for the six months ended June 30, 2020 and 2019, respectively.

expenses for the six months ended June 30, 2020 and 2019, respectively consists of the following:

Six months ended

June 30, 2020

Six months ended

June 30, 2019

$ (1,106,059 )

was $7,000 and $8,000 for the nine months ended September 30, 2020 and 2019, respectively.

expenses for the nine months ended September 30, 2020 and 2019, respectively consists of the following:

Nine months ended

September 30, 2020

Nine months ended

September 30, 2019

Professional fees

4 unchanged sentences

Total operating expenses

expenses for the six months ended June 30, 2020 and 2019 was $248,827 and $398,219, respectively.

The decrease in operating expenses

from 2019 to 2020 can be attributed to the decrease in professional fees ($269,173 for the six months ended June 30, 2020 versus

$111,269 for the six months ended June 30, 2020) as the Company utilized less services due to cash flow constraints;

and the increase

in general and administrative expense ($19,376 for the six months ended June 30, 2019 versus $57,957 for the six months ended

June 30, 2020) as the Company continued to incur reasonable administrative costs to run the Company.

expenses for the nine months ended September 30, 2020 and 2019 was $384,267 and $1,013,426, respectively.

The decrease in operating

expenses from 2019 to 2020 can be attributed to the decrease in professional fees ($170,771 for the nine months ended September

30, 2020 versus $356,248 for the nine months ended September 30, 2020) as the Company utilized less services due to cash flow

the decrease in stock based compensation ($2,176 for the nine months ended September 30, 2020 versus $463,917 for

the nine months ended September 30, 2019) and the increase in general and administrative expense ($41,067 for the nine months

ended September 30, 2019 versus $85,482 for the nine months ended September 30, 2020) as the Company continued to incur reasonable

administrative costs to run the Company.

Non-Operating

1 unchanged sentence

Non-operating

income (expense) for the six months ended June 30, 2020 and 2019 consists of the following:

Six months ended

June 30, 2020

Six months ended

June 30, 2019

income (expense) for the nine months ended September 30, 2020 and 2019 consists of the following:

Nine months ended

September 30, 2020

Nine months ended

September 30, 2019

Interest expense

1 unchanged sentence

Non-operating

income (expense) for the six months ended June 30, 2020 varied from the six months ended June 30, 2019 primarily due to an increase

in interest expense from as a result of the debt increase from 2019 to 2020 prior to conversion of this debt.

The majority of

the interest recorded by the Company consists of amortization of debt discount, BCF discount and the exchange premium resulting

in additional shares to the noteholders on conversion.

net loss for the six months ended June 30, 2020 and 2019 was $(519,318) and $(436,687), respectively.

of the Three Months Ended June 30, 2020 and 2019

following table sets forth information from our statements of operations for the three months ended June 30, 2020 and 2019:

income (expense) for the nine months ended September 30, 2020 varied from the nine months ended September 30, 2019 primarily due

to an increase in interest expense from as a result of the debt increase from 2019 to 2020 prior to conversion of this debt.

majority of the interest recorded by the Company consists of amortization of debt discount, BCF discount and the exchange premium

resulting in additional shares to the noteholders on conversion.

net loss for the nine months ended September 30, 2020 and 2019 was $(654,909) and $(1,106,059), respectively.

of the Three Months Ended September 30, 2020 and 2019

following table sets forth information from our statements of operations for the three months ended September 30, 2020 and 2019:

Three Months Ended

June 30, 2020

September 30, 2020

Three Months Ended

June 30, 2019

September 30, 2019

Operating expenses

2 unchanged sentences

Interest expense

was $0 for the three months ended June 30, 2020 and 2019, respectively.

expenses for the three months ended June 30, 2020 and 2019, respectively consists of the following:

was $7,000 and $8,000 for the three months ended September 30, 2020 and 2019, respectively.

expenses for the three months ended September 30, 2020 and 2019, respectively consists of the following:

Three months ended

June 30, 2020

September 30, 2020

Three months ended

June 30, 2019

September 30, 2019

Professional fees

4 unchanged sentences

Total operating expenses

expenses for the three months ended June 30, 2020 and 2019 was $128,453 and $173,016, respectively.

expenses for the three months ended September 30, 2020 and 2019 was $135,440 and $615,207, respectively.

The decrease in operating

expenses from 2019 to 2020 can be attributed to the decrease in professional fees ($102,638 for the three months ended June 30,

2020 versus $57,277 for the three months ended June 30, 2020) as the Company utilized less services due to cash flow constraints;

and the increase in general and administrative expense ($18,136 for the three months ended June 30, 2019 versus $22,603 for the

three months ended June 30, 2020) as the Company continued to incur reasonable administrative costs to run the Company.

expenses from 2019 to 2020 can be attributed to the decrease in professional fees ($59,502 for the three months ended September

30, 2020 versus $87,075 for the three months ended September 30, 2019) as the Company utilized less services due to cash flow

the decrease in stock based compensation ($0 in the three months ended September 30, 2020 versus $457,949 for the

three months ended September 30, 2020) and the increase in general and administrative expense ($21,691 for the three months ended

September 30, 2019 versus $27,526 for the three months ended September 30, 2020) as the Company continued to incur reasonable

administrative costs to run the Company.

Non-Operating

1 unchanged sentence

Non-operating

income (expense) for the three months ended June 30, 2020 and 2019 consists of the following:

income (expense) for the three months ended September 30, 2020 and 2019 consists of the following:

Three months ended

June 30, 2020

September 30, 2020

Three months ended

June 30, 2019

September 30, 2019

Interest expense

1 unchanged sentence

Non-operating

income (expense) for the three months ended June 30, 2020 varied from the three months ended June 30, 2019 primarily due to an

increase in interest expense from as a result of the debt increase from 2019 to 2020 prior to conversion of this debt.

of the interest recorded by the Company consists of amortization of debt discount, BCF discount and the exchange premium resulting

in additional shares to the noteholders on conversion.

net loss for the three months ended June 30, 2020 and 2019 was $(159,087) and $(200,305), respectively.

income (expense) for the three months ended September 30, 2020 varied from the three months ended September 30, 2019 primarily

due to an increase in interest expense from as a result of the debt increase from 2019 to 2020 prior to conversion of this debt.

The majority of the interest recorded by the Company consists of amortization of debt discount, BCF discount and the exchange

premium resulting in additional shares to the noteholders on conversion.

net loss for the three months ended September 30, 2020 and 2019 was $(135,591) and $(669,372), respectively.

and Capital Resources

June 30, 2020, the Company had a working capital deficit of $784,642 as compared to $1,479,689 at December 31, 2019.

six months ended June 30, 2020 the Company experienced negative cash flow from operations of $326,306 and it received $0 for investing

activities while adding $554,780 of cash flows from financing activities.

As of June 30, 2020, the Company had no commitments

for capital expenditures.

September 30, 2020, the Company had a working capital deficit of $870,233 as compared to $1,479,689 at December 31, 2019.

the nine months ended September 30, 2020 the Company experienced negative cash flow from operations of $510,227 and it received

$0 for investing activities while adding $504,780 of cash flows from financing activities.

As of September 30, 2020, the Company

had no commitments for capital expenditures.

used in operating activities was primarily a result of the Company’s net loss, and the adjustments to reconcile the net

2 unchanged sentences

Additionally there were increases in accrued payroll and accrued

The Company had no investing activities for the six-month periods ended June 30, 2020 and 2019, respectively.

six months ended June 30, 2020 and 2019, the Company had cash provided by financing activities of $554,780 and $402,000, respectively.

These activities were the result of proceeds received from notes payable (both related and unrelated parties) as well as from

sales of common stock and preferred stock.

The Company had no investing activities for the nine-month periods ended September 30, 2020 and 2019, respectively.

In the nine months ended September 30, 2020 and 2019, the Company had cash provided by financing activities of $504,780 and $737,000,

respectively.

These activities were the result of proceeds received from notes payable (both related and unrelated parties) as

well as from sales of common stock and preferred stock.

Company has generated material operating losses since inception.

The Company had a net loss of $519,318 for the six months ended

June 30, 2020, and a net loss of $436,687 for the six months ended June 30, 2019.

The Company expects to continue to experience

net operating losses.

Historically, the Company has relied upon investor funds to maintain its operations and develop the Company’s

The Company had a net loss of $654,909 for the nine months ended

September 30, 2020, and a net loss of $1,106,059 for the nine months ended September 30, 2019.

The Company expects to continue

to experience net operating losses.

Historically, the Company has relied upon investor funds to maintain its operations and develop

the Company’s business.

Company received $497,880 which were deposited into the Company’s accounts between April and June 2020.

3 unchanged sentences

exchanged their outstanding convertible notes payable of $525,000, $27,536 in accrued interest and $98,508 in an exchange premium

stipulated in the note agreements into shares of common stock through June 30, 2020.

stipulated in the note agreements into shares of common stock through September 30, 2020, and repaid $50,000 in promissory notes

the next 12 to 24 months, the Company believes it will cost approximately $5.0 million to $10.0 million to:

58 unchanged sentences

estimates under different assumptions or conditions.

During the period ended March 31, 2020, we believe there have been no significant

changes to the items disclosed as significant accounting policies in management’s notes to the consolidated financial statements

During the period ended September 30, 2020, we believe there have been no

significant changes to the items disclosed as significant accounting policies in management’s notes to the financial statements

in our annual report on Form 10-K for the year ended December 31, 2019, filed on April 28, 2020.

5 unchanged sentences

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-Q

Item 1. Financial Statements